A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

Phase 2

Completed

Brief Summary: This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection.

This study will evaluate the effect of Thymoglobulin and reduced doses of steroids to prevent renal transplant rejection and will provide a basis for future evaluations of Thymoglobulin as an immunosuppressive agent to help prevent renal transplant rejection.

Subjects meeting all inclusion and exclusion criteria are eligible to participate in this study. In addition to standard treatment, study participants will receive either Thymoglobulin with rapid discontinuation of steroids or steroids per hospital standards for at least the first 90 days after transplant. The treatment assignment is random and is not chosen by the subject or their physician.

Subjects will be monitored during treatment with Thymoglobulin and during the transplant hospitalization. Additional subject monitoring occurs at Months 1, 3, 6 and 12 following the transplant.

Approximately 150 study subjects from 15-20 transplant centers in the United States will be enrolled.

Recruitment & Eligibility

Inclusion Criteria

Adult living donor renal transplant recipient
Age greater than or equal to 18
If female and of childbearing potential: a) must not be lactating; b) must have a negative serum B-human chorionic gonadotropin (HCG) test within 24 hours prior to Study Day 0 (Day of Transplant) and; c) must agree to practice an acceptable and reliable form of contraception during the study; and
Signed informed consent

Exclusion Criteria

Human Leukocyte Antibody (HLA) identical matched living donor transplant recipient
> 2 previous transplants
Current panel reactive antibody (PRA) > 20%
History of a positive cross-match with the donor
Active donor or recipient serology positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV)
Loss of first kidney transplant in < 1 year
History of noncompliance in clinical trial(s)
History of chronic CS or immunosuppressive use except for inhaled CS to treat asthma
Use of any investigational products during the 90 days prior to screening
Requirement for multiple organ transplant
Patient without a functioning urinary bladder prior to transplant (e.g. patients with self catheterization will be excluded)
Known contraindication to administration of rabbit antithymocyte globulin
Currently abusing drugs or alcohol
In the opinion of the investigator, at high risk for poor compliance
In the opinion of the investigator, has a significant medical or psychosocial problem or unstable disease state that warrants exclusion from the study. Examples of significant problems include, but are not limited to morbid obesity and severe cardiac disease.

Primary Outcome Measures

Name	Time	Method
This study will evaluate the effect of Thymoglobulin and reduced doses of steroids to prevent renal transplant rejection, organ loss and death at 6 months.

Secondary Outcome Measures

Name	Time	Method
To evaluate patient kidney function after transplantation and the overall safety of Thymoglobulin in this patient population.

Locations (19): Keck USC School of Medicine
🇺🇸
Los Angeles, California, United States
Emory University
🇺🇸
Atlanta, Georgia, United States
University of Cincinnati Medical Center
🇺🇸
Cincinnati, Ohio, United States
University of California, Los Angeles Medical Center
🇺🇸
Los Angeles, California, United States
University of California, San Diego Medical Center
🇺🇸
San Diego, California, United States
Indiana University
🇺🇸
Indianapolis, Indiana, United States
Johns Hopkins University Hospital
🇺🇸
Baltimore, Maryland, United States
Saint Barnabas Medical Center
🇺🇸
Livingston, New Jersey, United States
University of Arkansas for Medical Science
🇺🇸
Little Rock, Arkansas, United States
University of Colorado Health Sciences Center
🇺🇸
Denver, Colorado, United States
Oschner Medical Center
🇺🇸
New Orleans, Louisiana, United States
California Pacific Medical Center
🇺🇸
San Francisco, California, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
Mount Sinai School of Medicine
🇺🇸
New York, New York, United States
Christ Hospital
🇺🇸
Cincinnati, Ohio, United States
Texas Transplant Institute
🇺🇸
San Antonio, Texas, United States
Medical College of Virginia
🇺🇸
Richmond, Virginia, United States
University of California, San Francisco
🇺🇸
San Francisco, California, United States
Medical College of Wisconsin
🇺🇸
Milwaukee, Wisconsin, United States